CN114957721A - 一种两性离子水凝胶及其制备方法和应用 - Google Patents
一种两性离子水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN114957721A CN114957721A CN202210597775.6A CN202210597775A CN114957721A CN 114957721 A CN114957721 A CN 114957721A CN 202210597775 A CN202210597775 A CN 202210597775A CN 114957721 A CN114957721 A CN 114957721A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- zwitterionic
- preparation
- gma
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 30
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 19
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 19
- 239000000787 lecithin Substances 0.000 claims abstract description 19
- 229940067606 lecithin Drugs 0.000 claims abstract description 19
- 235000010445 lecithin Nutrition 0.000 claims abstract description 19
- 239000002105 nanoparticle Substances 0.000 claims abstract description 19
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 18
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 18
- 229920001732 Lignosulfonate Polymers 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 235000019357 lignosulphonate Nutrition 0.000 claims abstract description 14
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 10
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 25
- 239000011259 mixed solution Substances 0.000 claims description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 235000010216 calcium carbonate Nutrition 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 13
- -1 methacrylglycidyl ether-modified hyaluronic acid Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 125000005641 methacryl group Chemical group 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- KPBSUKZGBOIPHW-UHFFFAOYSA-N 2-methylprop-2-enoic acid;2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound CC(=C)C(O)=O.C[N+](C)(C)CCOP(O)([O-])=O KPBSUKZGBOIPHW-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000001050 lubricating effect Effects 0.000 abstract description 7
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229940069978 calcium supplement Drugs 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 238000004630 atomic force microscopy Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UGRPVKNKPUXYKL-UHFFFAOYSA-N dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical compound CC(=C)C(=O)OCC[N+](C)(C)C#P=O UGRPVKNKPUXYKL-UHFFFAOYSA-N 0.000 description 1
- 230000002875 effect on osteoarthritis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007777 multifunctional material Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/028—Other inorganic materials not covered by A61L31/022 - A61L31/026
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2351/00—Characterised by the use of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers
- C08J2351/02—Characterised by the use of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers grafted on to polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2471/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2497/00—Characterised by the use of lignin-containing materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/24—Acids; Salts thereof
- C08K3/26—Carbonates; Bicarbonates
- C08K2003/265—Calcium, strontium or barium carbonate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/10—Encapsulated ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
本发明中公开了一种两性离子水凝胶的制备方法。本发明同时公开了该制备方法制备得到的两性离子水凝胶及其在骨关节炎治疗中的应用。本发明在两性离子水凝胶中引入卵磷脂包裹的碳酸钙纳米粒子(CaCO3@Lip)，既通过碳酸钙的分解调节关节腔内的酸性环境，又通过卵磷脂补充水凝胶的润滑性能，提供持续性润滑性能；同时通过引入双键改性的磺化木质素(MligS)作为交联剂，赋予水凝胶活性氧清除性能；通过引入甲基丙烯酸缩水甘油醚改性的透明质酸，进一步提高水凝胶的锁水能力以及抗炎效果；因此本发明中的两性离子水凝胶能显著提高骨关节炎的治疗效果；本发明中的制备方法简单，反应条件温和，无需特殊设备，适于工业化生产。
Description
技术领域
本发明涉及高分子功能材料领域，尤其涉及一种两性离子水凝胶及其制备方法和应用。
背景技术
骨关节炎(OA)是一种由年龄增长、意外创伤等潜在因素导致的慢性疾病。在病变部位，关节软骨基质之间降解，表层软骨润滑的功能逐渐丧失，从而使得运动过程中带来的软骨磨损加剧，最终使得OA逐渐恶化。另外，与其他炎症反应类似，患有OA的病人的关节液的pH降低且伴有大量的ROS产生，这两个因素也会不利于软骨的修复，因此，设计一种多功能材料来应对复杂的关节环境并实现OA治疗具有重要科学意义。
水凝胶材料是一种较为理想的用于模拟细胞外基质的材料。目前，聚阴离子水凝胶与聚两性离子水凝胶是两种常用于关节润滑的材料，这两种材料除了关节润滑与抗污性能外，尚不具备其他功能。
发明内容
本发明的目的在于解决现有技术中存在的水凝胶材料功能较为单一，对骨关节炎的治疗效果较差的问题，提供一种两性离子水凝胶及其制备方法和应用。
为解决上述技术问题，本发明采用的技术方案如下：一种两性离子水凝胶的制备方法，包括以下步骤：
S1、配置卵磷脂包裹的碳酸钙纳米粒子(CaCO3@Lip)和甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)的混合溶液a；
S2、配置两性离子单体、光引发剂和交联剂的混合溶液b；
S3、将S1中的混合溶液a和S2中的混合溶液b等体积混合并超声，制得预溶液，预溶液于紫外光下照5分钟后制备得到两性离子水凝胶。
优选地，所述S1的混合溶液a中CaCO3@Lip的浓度为1～20wt％；所述HA-GMA的浓度为2wt％。
优选地，所述S1中CaCO3@Lip的制备方法为：将CaCO3纳米粒子悬浮于卵磷脂溶液中，所述卵凝脂溶液浓度为5～20mg/mL；室温搅拌24小时，通过离心、洗涤、干燥得到卵磷脂包裹的碳酸钙纳米粒子。
优选地，所述S1中HA-GMA的制备方法为：将0.5005g透明质酸溶解于40mL去离子水中，然后加入140μL三乙胺，最后逐渐滴加1.6～6.4mL甲基丙烯酰缩水甘油醚(GMA)，充分混合后室温条件下继续反应24h，待反应结束后分别在1M的NaCl溶液和超纯水中透析12h；冻干后得到白色絮状产物，即为HA-GMA。
优选地，所述所述S2的混合溶液b中两性离子单体的浓度为2～6M；所述交联剂的浓度为两性离子单体浓度的1～5mol％；所述光引发剂的浓度为1wt％。
进一步优选，所述S2中两性离子单体为羧酸甜菜碱甲基丙烯酸酯(CBMA)、磺酸甜菜碱甲基丙烯酸酯(SBMA)或者磷酸胆碱甲基丙烯酸酯(MPC)中的一种。
进一步优选，所述S2中交联剂由PEGDA600和甲基丙烯酰磺化木质素(MligS)组成，所述PEGDA600和MligS的摩尔比为2～1:1～2。
进一步优选，所述甲基丙烯酰磺化木质素(MligS)的制备方法为：称取0.35g磺化木质素，将其溶解于6mL超纯水中，然后加入10μL三乙胺，加热到70℃并维持温度，再逐滴加入0.5～4mL甲基丙烯酸酐并搅拌18h；待反应结束后，降至室温，然后倒入过量冰乙醇中沉淀3次；真空干燥后获得棕色产物，即为MLigS。
本发明同时提供上述制备方法制备得到的两性离子水凝胶及其在骨关节炎治疗中的应用。
本发明所具有的有益效果：
一)本发明在两性离子水凝胶中引入卵磷脂包裹的碳酸钙纳米粒子(CaCO3@Lip)，既通过碳酸钙的分解调节关节腔内的酸性环境，又通过卵磷脂补充水凝胶的润滑性能，提供持续性润滑性能；同时通过引入双键改性的磺化木质素(MligS)作为交联剂，赋予水凝胶活性氧清除性能；通过引入甲基丙烯酸缩水甘油醚改性的透明质酸，进一步提高水凝胶的锁水能力以及抗炎效果；因此本发明中的两性离子水凝胶能显著提高骨关节炎的治疗效果；
二)本发明中的制备方法简单，反应条件温和，无需特殊设备，适于工业化生产。
附图说明
图1为实施例1中CaCO3纳米离子和CaCO3@Lip纳米离子的动态光散射(DLS)和扫描电镜(SEM)图；
图2为实施例1中CaCO3纳米离子和CaCO3@Lip纳米离子的原子力显微镜图(AFM)；
图3为实施例1中合成甲基丙烯酰磺化木质素(MLigS)的化学反应过程图；
图4为实施例1中MLigS核磁共振氢谱；
图5为实施例1中MLigS红外吸收光谱；
图6为实施例1中合成甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)的化学反应过程图；
图7为实施例1中HA-GMA核磁共振氢谱；
图8为实施例1中HA-GMA红外谱图；
图9为实施例1中制备得到的聚磺酸甜菜碱-透明质酸水凝胶外观图；
图10为实施例4中两性离子水凝胶的酸响应性能检测结果图；
图11为实施例5中两性离子水凝胶的润滑性能检测结果图；
图12为实施例6中两性离子水凝胶的压缩力学性能检测结果图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步的说明。
实施例1制备聚磺酸甜菜碱-透明质酸水凝胶
本实施例制备了聚磺酸甜菜碱-透明质酸水凝胶，本实施例中使用的两性离子单体为磺酸甜菜碱甲基丙烯酸酯(SBMA)。
(1)制备卵磷脂包裹碳酸钙纳米粒子(CaCO3@Lip)
将1100.2mg氯化钙(CaCl2)溶解于100mL Tris-HCl缓冲液中，记录为溶液A。将819.1mg氯化钠与106.2mg碳酸钠(Na2CO3)一起溶解于100mL HEPES缓冲液中，记录为溶液B。将溶液A与溶液B等体积混合，在冰水浴中缓慢搅拌过夜，然后通过离心、洗涤、干燥得到CaCO3纳米粒子。将得到的CaCO3纳米粒子悬浮于5mg/mL的卵磷脂溶液中，室温搅拌24小时，通过离心、洗涤、干燥得到CaCO3@Lip纳米粒子。
CaCO3纳米粒子和CaCO3@Lip纳米离子的动态光散射(DLS)和扫描电镜(SEM)图如附图1所示；CaCO3纳米粒子和CaCO3@Lip纳米离子的原子力显微镜图(AFM)如附图2所示。附图1-2显示，本实施例所制备的CaCO3纳米粒子为纳米尺度的球形粒子，其被卵磷脂包裹后，所得的CaCO3@Lip纳米离子的形貌仍为球形粒子，仅粒子尺寸增加。
(2)合成甲基丙烯酰磺化木质素(MLigS)
准确称取0.35g磺化木质素，将其溶解于6mL超纯水中，然后加入10μL三乙胺，将溶液加热到70℃。逐滴加入0.5mL的甲基丙烯酸酐(MAA)后继续高温搅拌18h。待反应结束后，将反应体系降至室温，然后倒入过量冰乙醇中沉淀3次。真空干燥后获得棕色产物，即为MLigS。
化学反应过程如附图3所示；MLigS核磁共振氢谱和红外吸收光谱分别如附图4、附图5所示。核磁谱图中双键的化学位移以及红外谱图中的双键的特征吸收峰都说明甲基丙烯酰磺化木质素的制备成功。
(3)合成甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)
本实施例中用于改性的透明质酸的分子量为400-1,000kDa。将0.5005g透明质酸溶解于40mL去离子水中，然后加入140μL三乙胺，最后逐渐滴加1.6mL的甲基丙烯酰缩水甘油醚(GMA)，充分混合后室温条件下继续反应24h。待反应结束后将粗产物进行透析(MWCO7,000)，分别在浓度为1M的NaCl溶液和超纯水中透析12h；冻干后可得到白色絮状产物，即为HA-GMA。
化学反应过程如附图6所示；HA-GMA核磁共振氢谱和红外吸收光谱分别如附图7和附图8所示。核磁谱图中双键的化学位移以及红外谱图中的双键的特征吸收峰都说明成功合成甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)。
(4)制备聚磺酸甜菜碱-透明质酸水凝胶
以水为溶剂配置卵磷脂包裹的碳酸钙纳米粒子(CaCO3@Lip)和甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)的混合溶液a(CaCO3@Lip的浓度为1wt％，HA-GMA的浓度为2wt％)；以水为溶剂配置两性离子单体、光引发剂和交联剂的混合溶液b(混合溶液b的配置如表1所示)；将混合溶液a和混合溶液b等体积混合并超声5分钟，制得预溶液；最后将预溶液倒入聚四氟乙烯模具，紫外光照5分钟后制备得到磺酸甜菜碱-透明质酸水凝胶。
本实施例制备得到的磺酸甜菜碱-透明质酸水凝胶的照片如附图9所示，SB代表SBMA，HA代表HA-GMA，ML代表MLigS以及CL代表CaCO3@Lip；引入两性离子单体或卵磷脂包裹碳酸钙纳米粒子后，水凝胶透明度有所改变，引入MLigS后，制备得到的水凝胶为黄色。
表1混合溶液b配置表
实施例2制备聚羧酸甜菜碱-透明质酸水凝胶
本实施例制备了聚羧酸甜菜碱-透明质酸水凝胶，本实施例中的两性离子单体为羧酸甜菜碱甲基丙烯酸酯(CBMA)。
本实施例与实施例1的制备方法的不同之处在于：步骤(1)中，CaCO3纳米粒子悬浮于10mg/mL的卵磷脂溶液中；步骤(2)中，加入2mL的甲基丙烯酸酐(MAA)；步骤(3)中，滴加3.2mL的甲基丙烯酰缩水甘油醚(GMA)；步骤(4)中，混合溶液a中CaCO3@Lip的浓度为10wt％；混合溶液b的配置如表2所示。
表2混合溶液b配置表
实施例3制备聚磷酸胆碱-透明质酸水凝胶
本实施例制备了聚磷酸胆碱-透明质酸水凝胶，本实施例中的两性离子单体为磷酸胆碱甲基丙烯酸酯(MPC)。
本实施例与实施例1的制备方法的不同之处在于：步骤(1)中，CaCO3纳米粒子悬浮于20mg/mL的卵磷脂溶液中；步骤(2)中，加入4mL的甲基丙烯酸酐(MAA)；步骤(3)中，滴加6.4mL的甲基丙烯酰缩水甘油醚(GMA)；步骤(4)中，混合溶液a中CaCO3@Lip的浓度为20wt％；混合溶液b的配置如表3所示。
表3混合溶液b配置表
实施例4通过pH计检测两性离子水凝胶的酸响应性能
分别将质量为5mg，10mg和50mg的聚磺酸甜菜碱-透明质酸水凝胶(由实施例1制备)放置于PBS缓冲液(pH＝5)中，于37℃浸泡不同时间后，用pH计测试溶液的pH。此外，在浸泡过程中，检测溶液中气泡产生的数量变化，用于判断酸响应性能。试验结果如附图10所示，SB代表PSBMA，HA代表HA-GMA，ML代表MLigS以及CL代表CaCO3@Lip；在引入卵磷脂包裹的碳酸钙的水凝胶中，水凝胶周围会出现大量气泡，说明碳酸钙在酸溶液中会发生分解，并且扩散到溶液中。
实施例5两性离子水凝胶的润滑性能检测
本实施例中，通过质构仪以及斜坡滑动试验检测水凝胶的润滑性能。
质构仪测试摩擦系数的参数是：滑动速度分别是0.1mm/s，0.2mm/s，0.5mm/s和1mm/s；压力分别设置为0.1N，0.2N，0.5N和1N。润滑剂采用不同pH的PBS缓冲液。
斜坡滑动试验的步骤是：将聚四氟乙烯模具倾斜一个高度并且固定，然后把充分水合的聚磺酸甜菜碱-透明质酸水凝胶(由实施例1制备)放置于模具上，通过相机观察水凝胶下滑情况。试验结果图附图11所示，SB代表SBMA，HA代表HA-GMA，ML代表MLigS以及CL代表CaCO3@Lip；在1s的时间点，SB-HA-ML-CL已经完全下滑至底部，体现更好地润滑性能。
实施例6两性离子水凝胶的压缩力学性能检测
本实施例中，通过万能力学试验机测试以实施例1中制备的聚磺酸甜菜碱-透明质酸水凝胶为检测对象进行压缩力学性能。其测试参数如下：样品为圆柱状样品，直径为10mm；高为8mm；压缩速度：0.2mm/s。试验结果如附图12所示，SB代表SBMA，HA代表HA-GMA，ML代表MLigS以及CL代表CaCO3@Lip；在引入MligS以及CaCO3@Lip后，水凝胶的压缩模量和压缩强度都明显提高。
本发明的说明书和附图被认为是说明性的而非限制性的，在本发明基础上，本领域技术人员根据所公开的技术内容，不需要创造性的劳动就可以对其中一些技术特征做出一些替换和变形，均在本发明的保护范围内。
Claims (10)
1.一种两性离子水凝胶的制备方法，其特征在于，包括以下步骤：
S1、配置卵磷脂包裹的碳酸钙纳米粒子(CaCO3@Lip)和甲基丙烯酰缩水甘油醚改性透明质酸(HA-GMA)的混合溶液a；
S2、配置两性离子单体、光引发剂和交联剂的混合溶液b；
S3、将S1中的混合溶液a和S2中的混合溶液b等体积混合并超声，制得预溶液，预溶液于紫外光下照5分钟后制备得到两性离子水凝胶。
2.根据权利要求1所述的制备方法，其特征在于，所述S1的混合溶液a中CaCO3@Lip的浓度为1～20wt％；所述HA-GMA的浓度为2wt％。
3.根据权利要求1所述的制备方法，其特征在于，所述S1中CaCO3@Lip的制备方法为：将CaCO3纳米粒子悬浮于卵磷脂溶液中，所述卵凝脂溶液浓度为5～20mg/mL；室温搅拌24小时，通过离心、洗涤、干燥得到卵磷脂包裹的碳酸钙纳米粒子。
4.根据权利要求1所述的制备方法，其特征在于，所述S1中HA-GMA的制备方法为：将0.5005g透明质酸溶解于40mL去离子水中，然后加入140μL三乙胺，最后逐渐滴加1.6～6.4mL甲基丙烯酰缩水甘油醚(GMA)，充分混合后室温条件下继续反应24h，待反应结束后分别在1M的NaCl溶液和超纯水中透析12h；冻干后得到白色絮状产物，即为HA-GMA。
5.根据权利要求1所述的制备方法，其特征在于，所述S2的混合溶液b中两性离子单体的浓度为2～6M；所述交联剂的浓度为两性离子单体浓度的1～5mol％；所述光引发剂的浓度为1wt％。
6.根据权利要求1所述的制备方法，其特征在于，所述S2中两性离子单体为羧酸甜菜碱甲基丙烯酸酯(CBMA)、磺酸甜菜碱甲基丙烯酸酯(SBMA)或者磷酸胆碱甲基丙烯酸酯(MPC)中的一种。
7.根据权利要求1所述的制备方法，其特征在于，所述S2中交联剂由PEGDA600和甲基丙烯酰磺化木质素(MligS)组成，所述PEGDA600和MligS的摩尔比为2～1:1～2。
8.根据权利要求7所述的制备方法，其特征在于，所述甲基丙烯酰磺化木质素(MligS)的制备方法为：称取0.35g磺化木质素，将其溶解于6mL超纯水中，然后加入10μL三乙胺，加热到70℃并维持温度，再逐滴加入0.5～4mL甲基丙烯酸酐并搅拌18h；待反应结束后，降至室温，然后倒入过量冰乙醇中沉淀3次；真空干燥后获得棕色产物，即为MLigS。
9.如权利要求1-8任一项所述制备方法制备得到的两性离子水凝胶。
10.如权利要求9所述的两性离子水凝胶在骨关节炎治疗中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597775.6A CN114957721B (zh) | 2022-05-30 | 2022-05-30 | 一种两性离子水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210597775.6A CN114957721B (zh) | 2022-05-30 | 2022-05-30 | 一种两性离子水凝胶及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114957721A true CN114957721A (zh) | 2022-08-30 |
| CN114957721B CN114957721B (zh) | 2024-04-26 |
Family
ID=82958420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210597775.6A Active CN114957721B (zh) | 2022-05-30 | 2022-05-30 | 一种两性离子水凝胶及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114957721B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115444840A (zh) * | 2022-09-15 | 2022-12-09 | 四川大学 | 一种前药、两性离子水凝胶及其制备方法、应用 |
| CN115572350A (zh) * | 2022-09-29 | 2023-01-06 | 四川大学 | 一种可降解双键透明质酸交联两性离子抗污水凝胶 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138528A1 (en) * | 2015-02-27 | 2016-09-01 | Wayne State University | Methods and compositions relating to biocompatible implants |
| CN107118300A (zh) * | 2017-04-18 | 2017-09-01 | 华南理工大学 | 含甜菜碱两性离子的水凝胶软性接触镜材料及其制备方法 |
| CN108676178A (zh) * | 2018-04-26 | 2018-10-19 | 济南大学 | 改性多糖水凝胶的制备方法及制备的改性多糖水凝胶 |
| CN111471320A (zh) * | 2020-05-25 | 2020-07-31 | 合肥学院 | 一种碳酸钙粉体的制备方法 |
| US20210171783A1 (en) * | 2018-08-14 | 2021-06-10 | University Of Washington | Zwitteronic double network hydrogels |
| CN113336536A (zh) * | 2021-05-31 | 2021-09-03 | 大连理工大学 | 一种无机非金属纳米颗粒组装的水凝胶材料及其在增材制造技术中的应用 |
| CN113454166A (zh) * | 2018-12-19 | 2021-09-28 | 泰普鲁特医疗技术有限责任公司 | 基于多糖和两性离子聚合物的水凝胶组合物及其使用方法 |
| CN114106232A (zh) * | 2021-11-25 | 2022-03-01 | 华南农业大学 | 一种两面粘附性不同的水凝胶及其制备方法和应用 |
-
2022
- 2022-05-30 CN CN202210597775.6A patent/CN114957721B/zh active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138528A1 (en) * | 2015-02-27 | 2016-09-01 | Wayne State University | Methods and compositions relating to biocompatible implants |
| CN107118300A (zh) * | 2017-04-18 | 2017-09-01 | 华南理工大学 | 含甜菜碱两性离子的水凝胶软性接触镜材料及其制备方法 |
| CN108676178A (zh) * | 2018-04-26 | 2018-10-19 | 济南大学 | 改性多糖水凝胶的制备方法及制备的改性多糖水凝胶 |
| US20210171783A1 (en) * | 2018-08-14 | 2021-06-10 | University Of Washington | Zwitteronic double network hydrogels |
| CN113454166A (zh) * | 2018-12-19 | 2021-09-28 | 泰普鲁特医疗技术有限责任公司 | 基于多糖和两性离子聚合物的水凝胶组合物及其使用方法 |
| CN111471320A (zh) * | 2020-05-25 | 2020-07-31 | 合肥学院 | 一种碳酸钙粉体的制备方法 |
| CN113336536A (zh) * | 2021-05-31 | 2021-09-03 | 大连理工大学 | 一种无机非金属纳米颗粒组装的水凝胶材料及其在增材制造技术中的应用 |
| CN114106232A (zh) * | 2021-11-25 | 2022-03-01 | 华南农业大学 | 一种两面粘附性不同的水凝胶及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| CHANGJIANG FAN等: "A tough double network hydrogel for cartilage tissue engineering", 《JOURNAL OF MATERIALS CHEMISTRY B》, vol. 1, no. 34, 25 June 2013 (2013-06-25), pages 4251 - 4258 * |
| 张亚萍: "基于LDHs的倍他米松衍生物药物缓释体系的制备及性能研究", 《中国博士学位论文全文数据库工程科技Ⅰ辑》, no. 12, 15 December 2018 (2018-12-15), pages 016 - 104 * |
| 罗春红 等: "光交联透明质酸水凝胶的制备及性能", 《高分子材料科学与工程》, vol. 27, no. 7, 31 July 2011 (2011-07-31), pages 163 - 166 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115444840A (zh) * | 2022-09-15 | 2022-12-09 | 四川大学 | 一种前药、两性离子水凝胶及其制备方法、应用 |
| CN115444840B (zh) * | 2022-09-15 | 2023-08-25 | 四川大学 | 一种前药、两性离子水凝胶及其制备方法、应用 |
| CN115572350A (zh) * | 2022-09-29 | 2023-01-06 | 四川大学 | 一种可降解双键透明质酸交联两性离子抗污水凝胶 |
| CN115572350B (zh) * | 2022-09-29 | 2024-04-19 | 四川大学 | 一种可降解双键透明质酸交联两性离子抗污水凝胶 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114957721B (zh) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114957721A (zh) | 一种两性离子水凝胶及其制备方法和应用 | |
| Zhao et al. | High‐strength and high‐toughness double‐cross‐linked cellulose hydrogels: a new strategy using sequential chemical and physical cross‐linking | |
| Zhou et al. | Biomimetic mineralization of anionic gelatin hydrogels: effect of degree of methacrylation | |
| Cheng et al. | Removal of methylene blue with hemicellulose/clay hybrid hydrogels | |
| Mamaghani et al. | Synthesis and microstructural characterization of GelMa/PEGDA hybrid hydrogel containing graphene oxide for biomedical purposes | |
| Wu et al. | Facile in-situ fabrication of novel organic nanoparticle hydrogels with excellent mechanical properties | |
| Wang et al. | A nanoporous hydrogel based on vinyl-functionalized alginate for efficient absorption and removal of Pb2+ ions | |
| Ren et al. | Quaternized xylan/cellulose nanocrystal reinforced magnetic hydrogels with high strength | |
| Chen et al. | Synthesis and characterization of hydroxypropyl cellulose from bacterial cellulose | |
| Gao et al. | The modification of collagen with biosustainable POSS graft oxidized sodium alginate composite | |
| CN108295306A (zh) | 一种含介孔纳米磷酸钙颗粒填料的三维打印水凝胶材料及其制备方法 | |
| Pourjavadi et al. | Preparation of PVA nanocomposites using salep-reduced graphene oxide with enhanced mechanical and biological properties | |
| Palangetic et al. | From near hard spheres to colloidal surfboards | |
| Li et al. | Phytic acid-assist for self-healing nanocomposite hydrogels with surface functionalization of cellulose nanocrystals via SI-AGET ATRP | |
| CN107693803B (zh) | 一种负载氧化锰的杂化海藻酸钠纳米凝胶的制备方法 | |
| Xiao et al. | Cartilage-bioinspired, tough and lubricated hydrogel based on nanocomposite enhancement effect | |
| Jiang et al. | Surface engineering of cellulose nanocrystals via SI-AGET ATRP of glycidyl methacrylate and ring-opening reaction for fabricating self-healing nanocomposite hydrogels | |
| US7365120B2 (en) | Polymer composite, stretched product thereof and production processes therefor | |
| KR101286347B1 (ko) | 덱스트란 설페이트를 포함하는 블록공중합체로 도포된 산화철 복합 나노입자, 이의 제조방법 및 이를 포함하는 동맥경화 진단용 조영제 | |
| Aziz et al. | Improving Adhesive Properties of Cellulose Nanocrystals Modifying By 3-Glycidoxypropyltrimethoxy Silane (KH-560) Coupling Agents | |
| Li et al. | Preparation, Properties, and Mechanism of Anionic and Cationic Cellulose Nanocrystals/Waterborne Polyurethane Composite Films. | |
| Sobh et al. | Synthesis and characterization of magnetic sponge nanocomposite for cleaning archeological lime stones | |
| Zhang et al. | Comparative study on the effect of inhibitory methods on the color and gelation properties of alkali induced heat-set konjac gel from Amorphophallus bulbifer | |
| Kim et al. | Physicochemical properties of chitosan-poly (ethylene oxide) hydrogel modified through linoleic acid | |
| Xiao et al. | Effect of surface grafted hydroxyapatite on the improved performance of hydroxyapatite/poly (ε-caprolactone) scaffold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |